Doer Biologics' DR30206 Granted IND Approval in China for Combination Therapy in Advanced or Metastatic Gastrointestinal Tumors
Doer Biologics
Biological Drug Developer
On April 3, 2025, Doer Biologics received the "Drug Clinical Trial Approval Notice" (Notice No. 2025LP00993) issued by the National Medical Products Administration (NMPA). The clinical trial application for DR30206 Injection, a Class 1 new biologic drug developed by Doer Biologics, in combination with standard chemotherapy for patients with advanced or metastatic gastrointestinal tumors, has been approved. This marks the second approved clinical indication for DR30206, aiming to evaluate the safety, tolerability, and preliminary efficacy of DR30206 in combination with standard chemotherapy regimens in gastrointestinal tumors.
DR30206 for Injection is a Class 1 therapeutic biologic independently developed by Doer Biologics with global intellectual property rights. DR30206 is an antibody fusion protein targeting PD-L1, VEGF, and TGF-β. By blocking the PD-1/PD-L1 signaling pathway, it restores the proliferation of exhausted CD8+T cells. By specifically binding to free VEGF and TGF-β, it reduces the formation of tumor neovascularization while relieving immunosuppression, thereby achieving the purpose of killing tumors. To date, there are no antibody fusion protein drugs targeting PD-L1, VEGF, and TGF-β simultaneously available on the global market.
Dr. Huang Yanshan
Founder & CEO of Doer Biologics
Dr. Huang Yanshan, founder and CEO of Doer Biologics, stated: "DR30206 is an innovative tri-specific biologic drug designed, modified, and developed using Doer Biologics' proprietary SMART-VHHBody and MultipleBody® platform technologies. It exhibits high affinity and excellent specificity for the three targets: PD-L1, VEGF, and TGF-β. In preclinical experiments, DR30206 demonstrated potent anti-tumor activity across multiple models related to gastrointestinal tumors."
Dr. Yongliang Fang
Chief Operating Officer of Doer Biologics
Dr. Yongliang Fang, Chief Operating Officer of Doer Biologics, commented: "We are encouraged by the newly approved clinical indications for DR30206. The ongoing Phase I clinical trial of DR30206 has demonstrated good human tolerability and preliminary efficacy in patients with various types of solid tumors. We look forward to DR30206 in combination with standard chemotherapy providing new treatment options for more patients with gastrointestinal tumors in the future."
The clinical trial of DR30206 for injection in China was approved by the National Medical Products Administration in June 2023 (Approval Notice No. 2023LP01231), with the indication for advanced solid tumors. More information about the Phase I clinical trial of DR30206 in China can be found on the Drug Clinical Trial Registration and Information Disclosure Platform (Registration No.: CTR20233502).
About Doer Biologics
Zhejiang Doer Biologics Co., Ltd. ("Doer Biologics") is a clinical-stage biopharmaceutical company focused on the discovery and development of multi-specific biotherapeutics based on multi-domain structures to address unmet medical needs in the fields of metabolic diseases and cancer.
Doer Biologics has developed a variety of proprietary platform technologies, including xLONGylation®, MultipleBody®, AccuBody®, and SMART-VHHBody.
For more information about Doer Biologics, please visit www.doerbio.com.